250 related articles for article (PubMed ID: 16022084)
1. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them.
Salzer W
Perit Dial Int; 2005; 25(4):313-9. PubMed ID: 16022084
[TBL] [Abstract][Full Text] [Related]
2. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Jones RN; Low DE; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
[TBL] [Abstract][Full Text] [Related]
3. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
4. Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014.
Zelenitsky SA; Howarth J; Lagacé-Wiens P; Sathianathan C; Ariano R; Davis C; Verrelli M
Perit Dial Int; 2017; 37(2):170-176. PubMed ID: 27738087
[TBL] [Abstract][Full Text] [Related]
5. Positive dialysate gram stain predicts outcome of empirical antibiotic therapy for peritoneal dialysis-associated peritonitis.
Lee CC; Sun CY; Chang KC; Wu MS
Ther Apher Dial; 2010 Apr; 14(2):201-8. PubMed ID: 20438543
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
7. The pathogen spectrum and resistance in patients with peritoneal dialysis-associated peritonitis: A single-center, observational clinical study
.
Yang L; Gong N; Zhou H; Jiang J
Clin Nephrol; 2019 Jul; 92(1):44-51. PubMed ID: 31131821
[TBL] [Abstract][Full Text] [Related]
8. Future trends in the treatment of serious Gram-positive infections.
Metzger R; Bonatti H; Sawyer R
Drugs Today (Barc); 2009 Jan; 45(1):33-45. PubMed ID: 19271030
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
10. Novel agents for resistant Gram-positive infections--a review.
Strahilevitz J; Rubinstein E
Int J Infect Dis; 2002 Mar; 6 Suppl 1():S38-46. PubMed ID: 12044288
[TBL] [Abstract][Full Text] [Related]
11. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
Klastersky J
Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
[TBL] [Abstract][Full Text] [Related]
12. A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: is empiric vancomycin still indicated for some patients?
Kan GW; Thomas MA; Heath CH
Perit Dial Int; 2003; 23(5):465-8. PubMed ID: 14604199
[TBL] [Abstract][Full Text] [Related]
13. Peritonitis in peritoneal dialysis patients in Uruguay.
Gadola L; Orihuela L; Pérez D; Gómez T; Solá L; Chifflet L; Mautone M; Torres E; Rodriguez G
Perit Dial Int; 2008; 28(3):232-5. PubMed ID: 18474913
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin-resistant enterococcus infection is a rare complication in patients receiving PD on an outpatient basis.
Ng R; Zabetakis PM; Callahan C; Krapf R; Sasak C; Fritzsch S; Pollock A; Balter P; Michelis MF
Perit Dial Int; 1999; 19(3):273-4. PubMed ID: 10433167
[No Abstract] [Full Text] [Related]
15. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
Lee SY; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
[TBL] [Abstract][Full Text] [Related]
17. Novel pharmaceutical molecules against emerging resistant gram-positive cocci.
Manfredi R; Sabbatani S
Braz J Infect Dis; 2010; 14(1):96-108. PubMed ID: 20428664
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial resistance among gram-positive organisms in the intensive care unit.
Clark NM; Hershberger E; Zervosc MJ; Lynch JP
Curr Opin Crit Care; 2003 Oct; 9(5):403-12. PubMed ID: 14508154
[TBL] [Abstract][Full Text] [Related]
19. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
Lundstrom TS; Sobel JD
Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
[TBL] [Abstract][Full Text] [Related]
20. Newer treatment options for skin and soft tissue infections.
Raghavan M; Linden PK
Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
